Puma Biotech (PBYI) Tops Q4 EPS by 31c

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.21, $0.31 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $51 million versus the consensus estimate of $46.85 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Goldman Sachs Upgrades Rohm Co Ltd. (6963:JP) (ROHCY) to Buy
• ABM Industries (ABM) Misses Q2 EPS by 2c ; Offers Guidance
• Deutsche Bank Starts TP Icap (TCAP:LN) (TULLF) at Buy